Brentuximab Vedotin is an antibody-drug conjugate specifically designed for the treatment of certain types of lymphomas. It combines a monoclonal antibody targeting CD30, a protein frequently expressed on the surface of cancerous cells, with a potent cytotoxic agent, monomethyl auristatin E (MMAE). This combination allows for targeted delivery of the cytotoxic agent, minimizing damage to healthy cells.
